Literature DB >> 10189423

Prevalence of Mycobacterium tuberculosis infection among injection drug users in Toronto.

I D Rusen1, L Yuan, M E Millson.   

Abstract

BACKGROUND: Injection drug users are at increased risk of Mycobacterium tuberculosis infection and active tuberculosis (TB). The primary objective of this study was to determine the prevalence of M. tuberculosis infection among injection drug users in Toronto, as indicated by a positive tuberculin skin test result. An additional objective was to identify predictors of a positive skin test result in this population.
METHODS: A cross-sectional study was carried out involving self-selected injection drug users in the city of Toronto. A total of 171 participants were recruited through a downtown Toronto needle-exchange program from June 1 to Oct. 31, 1996.
RESULTS: Of 167 subjects tested, 155 (92.8%) returned for interpretation of their skin test result within the designated timeframe (48 to 72 hours). Using a 5-mm cut-off, the prevalence rate of positive tuberculin skin test results was 31.0% (95% confidence interval 23.8% to 38.9%). Birth outside of Canada and increasing age were both predictive of a positive result.
INTERPRETATION: There is a high burden of M. tuberculosis infection in this population of injection drug users. The compliance observed with returning for interpretation of skin test results indicates that successful TB screening is possible among injection drug users.

Entities:  

Mesh:

Year:  1999        PMID: 10189423      PMCID: PMC1230158     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  11 in total

1.  Needle exchange is not enough: lessons from the Vancouver injecting drug use study.

Authors:  S A Strathdee; D M Patrick; S L Currie; P G Cornelisse; M L Rekart; J S Montaner; M T Schechter; M V O'Shaughnessy
Journal:  AIDS       Date:  1997-07       Impact factor: 4.177

2.  Tuberculosis infection in a metropolitan city: an epidemiologic review.

Authors:  S C Stein
Journal:  Am Rev Respir Dis       Date:  1969-02

3.  Reading the tuberculin skin test. Who, when, and how?

Authors:  T P Howard; D A Solomon
Journal:  Arch Intern Med       Date:  1988-11

Review 4.  The negative tuberculin test. Tuberculin, HIV, and anergy panels.

Authors:  E L Pesanti
Journal:  Am J Respir Crit Care Med       Date:  1994-06       Impact factor: 21.405

5.  Tuberculous infection in an urban population analysis of 1000 routine Mantoux tests.

Authors:  C Bilgi
Journal:  Can J Public Health       Date:  1980 Sep-Oct

6.  Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group.

Authors:  N Markowitz; N I Hansen; T C Wilcosky; P C Hopewell; J Glassroth; P A Kvale; B T Mangura; D Osmond; J M Wallace; M J Rosen; L B Reichman
Journal:  Ann Intern Med       Date:  1993-08-01       Impact factor: 25.391

Review 7.  Tuberculosis in drug users.

Authors:  D C Perlman; N Salomon; M P Perkins; S Yancovitz; D Paone; D C Des Jarlais
Journal:  Clin Infect Dis       Date:  1995-11       Impact factor: 9.079

Review 8.  A statistical chronicle of tuberculosis in Canada: Part II. Risk today and control.

Authors:  A Brancker; D A Enarson; S Grzybowski; E S Hershfield; C W Jeanes
Journal:  Health Rep       Date:  1992       Impact factor: 4.796

9.  Tuberculin reactions among attendees at a methadone clinic: relation to infection with the human immunodeficiency virus.

Authors:  R R MacGregor; D Dunbar; A L Graziani
Journal:  Clin Infect Dis       Date:  1994-12       Impact factor: 9.079

10.  Maintaining low HIV seroprevalence in populations of injecting drug users.

Authors:  D C Des Jarlais; H Hagan; S R Friedman; P Friedmann; D Goldberg; M Frischer; S Green; K Tunving; B Ljungberg; A Wodak
Journal:  JAMA       Date:  1995-10-18       Impact factor: 56.272

View more
  7 in total

Review 1.  Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users.

Authors:  Antonio L Estrada
Journal:  Public Health Rep       Date:  2002       Impact factor: 2.792

2.  Tuberculosis screening in a novel substance abuse treatment center in Malaysia: implications for a comprehensive approach for integrated care.

Authors:  Haider Abdulrazzaq Abed Al-Darraji; Kee Cheong Wong; David Gan Eng Yeow; Jeannia Jiani Fu; Kelsey Loeliger; Christopher Paiji; Adeeba Kamarulzaman; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2013-09-24

Review 3.  Tuberculosis and illicit drug use: review and update.

Authors:  Robert G Deiss; Timothy C Rodwell; Richard S Garfein
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

4.  High prevalence of latent tuberculosis infection among injection drug users in Tijuana, Mexico.

Authors:  R S Garfein; R Lozada; L Liu; R Laniado-Laborin; T C Rodwell; R Deiss; J Alvelais; A Catanzaro; P G Chiles; S A Strathdee
Journal:  Int J Tuberc Lung Dis       Date:  2009-05       Impact factor: 2.373

5.  Tuberculosis testing among populations with high HIV risk in Tijuana, Baja California, Mexico.

Authors:  Michele G Velasquez; Rafael Laniado-Laborin; Timothy C Rodwell; Paris Cerecer; Remedios Lozada; Jazmine Cuevas-Mota; Jose Luis Burgos; Richard S Garfein
Journal:  Rev Panam Salud Publica       Date:  2012-07

6.  Mycobacterium tuberculosis infection among persons who inject drugs in San Diego, California.

Authors:  R F Armenta; K M Collins; S A Strathdee; M A Bulterys; F Munoz; J Cuevas-Mota; P Chiles; R S Garfein
Journal:  Int J Tuberc Lung Dis       Date:  2017-04-01       Impact factor: 2.373

7.  Risk for latent and active tuberculosis in Germany.

Authors:  Christian Herzmann; Giovanni Sotgiu; Oswald Bellinger; Roland Diel; Silke Gerdes; Udo Goetsch; Helga Heykes-Uden; Tom Schaberg; Christoph Lange
Journal:  Infection       Date:  2016-11-19       Impact factor: 3.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.